Celcuity Inc. CELC
Regular-session close
After hours · Nov 20, 4:52 PM ET
- YTD
- -46.51%
- 1 year
- -43.24%
5D -10.20 (-15.99%)
- Market cap
- 2.61B
- EPS (ttm)
- -4.72
- Shares out
- 48.93M
- Forward P/E
- -10658.00
- YTD return
- -46.51%
- 1-year return
- -43.24%
- 50-day average
- 69.79
- 200-day average
- 97.40
- Enterprise value
- 2.88B
- Free cash flow
- -182.41M
- Volume
- 636.53K
- Avg volume
- 1.25M
- Open
- 55.02
- Previous close
- 56.31
- Day's range
- 53.20 – 57.00
- 52-week range
- 53.35 – 144.98
- Beta
- 0.13
- Analysts
- Strong Buy
- Price target
- 150.85 (+182.7%)
- Earnings date
- Mar 24, 2027
Key statistics
- Total cash
- 642.70M
- Total debt
- 755.07M
- Return on equity
- -1192.88%
- Short % of float
- 31.59%
Fundamental scorecard
1 of 25 checks passed on CELC’s reported financials
1of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 130.00
- Target (mean)
- 150.85
- Target (high)
- 177.00
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 24, 2027
Expected Mar 24, 2027. Consensus EPS estimate -1.04.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 24, 2027 | Mar 30, 2027 | -1.34 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -1.51 | -1.21 | +0.30 | +19.87% |
| Aug 13, 2026 | Jun 30, 2026 | -1.16 | -1.44 | -0.28 | -24.14% |
| May 14, 2026 | Mar 31, 2026 | -1.04 | -0.97 | +0.07 | +6.73% |
| Mar 25, 2026 | Dec 31, 2025 | -1.06 | -0.97 | +0.09 | +8.49% |
| Nov 12, 2025 | Sep 30, 2025 | -1.02 | -0.92 | +0.10 | +9.80% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 6, 2026 | Guggenheim | main | Buy | Buy |
| Nov 2, 2026 | Guggenheim | main | Buy | Buy |
| Oct 22, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Oct 21, 2026 | TD Cowen | reit | Buy | Buy |
| Sep 30, 2026 | Needham | main | Buy | Buy |
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celcuity.com
News
Celcuity, Inc. $CELC Stock Sold by AlTi Global Inc. Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment
Celcuity, Inc. $CELC Shares Newly Bought by ACT Capital Partners L.P. Celcuity's Supplemental New Drug Application For REVTORPYK Accepted for FDA Review To Treat Hormone Receptor Positive
Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150
Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169
Celcuity Q3 2026 Earnings Call Transcript Celcuity Q3 Adj. EPS $(1.21) Beats $(1.43) Estimate, Sales $0.00 Miss $1.563M Estimate
Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140
Your note
Sign in to keep a note on CELC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Unknown | Sale | Jul 13, 2026 | 0 |
| BULLER RICHARD E | Director | Stock Award(Grant) | Jun 4, 2026 | 9,319 |
| DALVEY DAVID F | Director | Stock Award(Grant) | Jun 4, 2026 | 66,530 |
| FURCHT LEO M.D. | Director | Stock Award(Grant) | Jun 4, 2026 | 12,530 |
| HAHNE VICKY | Chief Financial Officer | Stock Award(Grant) | Aug 13, 2026 | 37,808 |
| LAING LANCE G PH.D. | Officer and Director | Stock Award(Grant) | Aug 13, 2026 | 1,271,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.80% | 4,815,792 | 256.63M | Sep 29, 2026 |
| RTW Investments LP | 6.73% | 3,304,903 | 176.12M | Sep 29, 2026 |
| Blackrock Inc. | 6.47% | 3,177,631 | 169.34M | Sep 29, 2026 |
| Perceptive Advisors Llc | 6.47% | 3,179,794 | 169.45M | Sep 29, 2026 |
| Deerfield Management Company, L.P | 4.88% | 2,397,664 | 127.77M | Sep 29, 2026 |
| State Street Corporation | 4.19% | 2,056,176 | 109.57M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 1,394,056 | 74.29M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.44% | 1,197,169 | 63.80M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.03% | 996,070 | 53.08M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.98% | 479,203 | 25.54M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 0.94% | 461,836 | 24.61M | Oct 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.89% | 436,212 | 23.25M | Jun 29, 2026 |
